Veru Inc. (NASDAQ:VERU) Given Consensus Recommendation of “Buy” by Brokerages

Veru Inc. (NASDAQ:VERU – Get Rating) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $29.17.

A number of brokerages recently issued reports on VERU. Oppenheimer dropped their target price on Veru from $20.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 14th. HC Wainwright dropped their target price on Veru from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, February 10th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of VERU. Goldman Sachs Group Inc. grew its stake in Veru by 4,643.0% in the second quarter. Goldman Sachs Group Inc. now owns 4,880,509 shares of the company’s stock valued at $55,150,000 after purchasing an additional 4,777,610 shares in the last quarter. Boxer Capital LLC bought a new position in Veru in the third quarter valued at approximately $28,800,000. Morgan Stanley boosted its stake in shares of Veru by 15.0% during the 4th quarter. Morgan Stanley now owns 7,293,792 shares of the company’s stock worth $38,511,000 after acquiring an additional 949,478 shares during the period. Driehaus Capital Management LLC bought a new position in shares of Veru during the 2nd quarter worth approximately $5,312,000. Finally, Renaissance Technologies LLC bought a new position in shares of Veru during the 3rd quarter worth approximately $4,690,000. 48.87% of the stock is currently owned by institutional investors.

Veru Price Performance

NASDAQ VERU opened at $2.24 on Friday. The firm has a market cap of $180.68 million, a P/E ratio of -1.57 and a beta of -0.15. The stock’s 50-day moving average is $4.94 and its 200-day moving average is $8.33. Veru has a one year low of $2.21 and a one year high of $24.55.

Veru (NASDAQ:VERU – Get Rating) last released its quarterly earnings results on Monday, December 5th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.22). Veru had a negative return on equity of 119.37% and a negative net margin of 412.01%. The business had revenue of $2.59 million for the quarter, compared to analyst estimates of $11.51 million. Equities analysts anticipate that Veru will post -1.36 EPS for the current year.

Veru Company Profile

(Get Rating)

Veru, Inc is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT.